BL 1249
目录号 : GC10094BL 1249 是一种非甾体抗炎药 (NSAID) 和钾通道激活剂。
Cas No.:18200-13-0
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
[(5, 6, 7, 8-tetrahydro-naphthalen-1-yl)-[2-(1H-tetrazol-5-yl)-phenyl]-amine], named BL 1249, is a putative potassium channel opener with bladder-relaxant properties. In cultured bladder smooth muscle cells, BL 1249 decreased DiBAC4 (3) fluorescence in a concentration-dependent manner with an EC50 of 1.26 ± 0.6 µM. In human bladder cells, BL 1249 resulted in hyperpolarization in a concentration-dependent manner and yielded an EC50 of 1.49±0.08 µM. BL 1249 relaxed 30 mM KCl precontracted bladder strips in a concentration-dependent manner and yielded an EC50 of 1.1 ± 0.37 µM [1].
There are several types of potassium channels in urinary bladder myocytes and they are important in determining contractility and excitability of bladder smooth muscle. These channels include maxi-K+, KATP, members of the voltage-gated Kv family, SK family and, possibly, members of the KCNQ family. Open potassium channels can increase potassium efflux from the cell and produce membrane potential hyperpolarization, thereby decrease the activation of voltage-dependent calcium channels [1].
In human bladder myocytes, BL 1249 produced large instantaneously non-inactivating, activating outward currents that were readily reversible following drug washout. The BL 1249-induced current was hence of a reversal potential of near -80 mV under the physiological K+ gradient, this indicated that the current is carried by K+ ions [1].
In anesthetized rats, BL 1249 at a concentration of 1 mg/kg significantly decreased (p< 0.01) micturition contractions during the 15-min period immediately following dosing; for the 15- to 30-min period, the decrease was significant but less (p< 0.05). Administration of BL 1249 at a concentration of 1 mg/kg had no effect on mean arterial blood pressure (MABP) during the 0- to 15-min period immediately following administration. During the 15- to 30-min period, BL 1249 administration increased MABP by less than 10% [1].
Reference:
[1]. Svetlana Tertyshnikova, Ronald J. Knox, Mary Jane Plym, et al. BL-1249 [(5, 6, 7, 8-Tetrahydro-naphthalen-1-yl)-[2-(1H-tetrazol-5-yl)-phenyl]-amine]: A Putative Potassium Channel Opener with Bladder-Relaxant Properties. The Journal of Pharmacology and Experimental Therapeutics, 2015, 313(1):250-259.
Cas No. | 18200-13-0 | SDF | |
化学名 | N-(2-(2H-tetrazol-5-yl)phenyl)-5,6,7,8-tetrahydronaphthalen-1-amine | ||
Canonical SMILES | C1(CCCCC1=CC=C2)=C2NC3=CC=CC=C3C4=NNN=N4 | ||
分子式 | C17H17N5 | 分子量 | 291.35 |
溶解度 | <29.14mg/ml in 1eq. NaOH; <29.14mg/ml in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.4323 mL | 17.1615 mL | 34.323 mL |
5 mM | 0.6865 mL | 3.4323 mL | 6.8646 mL |
10 mM | 0.3432 mL | 1.7161 mL | 3.4323 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。